

TABLE OF CONTENTS

	Page
DECLARATION	ii
DEDICATION	iii
PUBLICATIONS AND PRESENTATIONS	iv
ABSTRACT	v
ACKNOWLEDGEMENTS	vi
LIST OF TABLES	vii
TABLE OF CONTENTS	ix

VOLUME I

1.0	INTRODUCTION	1
1.2	Description and definition of non compliance	1
1.2	Implications for research	5
1.3	The inability of doctors to consistently detect compliance	7
1.4	Financial implications	9
2.0	THE PERVASIVENESS OF NON COMPLIANCE IN MEDICAL FIELDS OTHER THAN ONCOLOGY	11
2.1	Hypertension	11
2.2	Stroke	14
2.3	Cardiac conditions	14
2.3.1	Heart failure	15
2.3.2	Cardiac rehabilitation	15
2.3.3	Heart transplant	16
2.3.4	Endocarditis	16
2.3.5	Hypercholesterolaemia	16
2.4	Respiratory conditions	17
2.4.1	Asthma	18
2.5	Diabetes	19
2.6	Antibiotics	20
2.6.1	Prophylactic antibiotic therapy	21
2.7	Haemodialysis and renal transplant	21
2.8	Tuberculosis	22
2.9	HIV/AIDS	25
2.9.1	HIV in Women	27
2.9.2	HIV in Childhood and Adolescence	27
2.10	Genitourinary conditions	28
2.11	Ophthalmic conditions	29
2.12	Neurological conditions	29
2.13	Psychiatric conditions	30
2.14	Dental and peridontal	30
2.15	Health practices	31

2.16	Immunization	32
2.17	Malaria	33
2.18	Geriatric	34
2.19	Other conditions	35
2.19.1	Allergen	36
2.19.2	Hormone replacement therapy	36
2.20	General follow up and patient behavior	37
2.21	Medicines	38
2.22	Summary	38
3.0	THE MANY DIFFERENT FORMS OF NON COMPLIANCE	40
3.1	Irregularities in taking medication	40
3.2	Non compliance with other forms of treatment	43
3.2.1	Haemodialysis and Renal Transplant	43
3.2.2	Diabetes	44
3.2.3	Non Compliance with Immunization	45
3.2.4	Non Compliance with other medical conditions	46
3.3	Summary	47
4.0	MEASUREMENT OF NON COMPLIANCE	48
4.1	Measurement methods used	53
4.1.1	The Medication Event Monitoring System (MEMS)	54
4.2	Summary	57
5.0	PREDICTORS AND REASONS FOR NON COMPLIANCE	58
5.1	Personal beliefs and distortions	58
5.1.1	Distortions about Particular Groups of Medicines	61
5.1.2	The Diagnosis	65
5.1.3	Self (Mis)Perception of Success	67
5.1.4	The Health Belief Model	68
5.2	Doctor-patient communication	70
5.3	Psychiatric conditions	72
5.3.1	Depression	74
5.4	Personality factors	75
5.5	The death instinct	77
5.6	Locus of control	78
5.7	Age	80
5.7.1	Younger vs. Older patients	80
5.7.2	Childhood non-compliance	81
5.7.3	Adolescence	83
5.7.4	The elderly and compliance	86
5.7.4.1	Handling/opening of medication containers	87
5.8	Sex differences	88
5.9	Lack of sufficient knowledge	90
5.9.1	Educational level	91
5.9.2	Aculturation	92

5.10	Illiteracy	92
5.11	Inconvenience and lack of effort	93
5.12	Side effects	94
5.12.1	The side effects of immunization	97
5.13	Dosage	98
5.14	Length of therapy	99
5.15	Avoidance	101
5.15.1	Forgetfulness	102
5.16	Support systems	103
5.17	Socioeconomic status	105
5.17.1	Transport	107
5.18	Fear of social stigma	108
5.19	Lack of medical facilities	109
5.20	Post traumatic stress	110
5.21	Summary	111
6.0	STRATEGIES TO COMBAT NON-COMPLIANCE	113
6.1	The urgent need for effective interventions	114
6.2	Acute vs. Long term compliance	115
6.3	Individualized intervention	116
6.4	Assessment of beliefs	122
6.4.1	The health belief model and locus of control	125
6.5	Education	127
6.5.1	Assess limitations of patients	132
6.6	Strengthening the belief in control or cure	133
6.7	Quality of life	133
6.8	Practical ways of improving compliance	134
6.8.1	Interactive and Non-Interactive Interventions	135
6.8.2	Monitoring and Supervision	136
6.8.3	Directly Observed Therapy(DOT) and Tuberculosis	137
6.8.4	The Role of Cues and Reminders in Medical Compliance	139
6.8.5	Appointment Scheduling	143
6.8.6	Uniting Clinics	143
6.8.7	Changes in Life Style	144
6.8.8	Reducing the Number of Doses	145
6.8.9	Devices	146
6.8.10	Financial Rewards as Reinforcers	147
6.8.11	Drug Packaging	148
6.9	Social and family support	148
6.10	Psychiatric and psychological interventions	150
6.10.1	Post traumatic stress and trauma debriefing	151
6.10.2	Cognitive behaviour therapy and other forms of behaviour therapy	153
6.11	Nurse-patient relationship	157
6.12	Pharmacist - patient relationship	159
6.13	Doctor-patient relationship	160
6.14	The judgemental nature of the term "compliance"	165

6.15	Patient as partner	166
6.16	Summary	173
7.0	ALTERNATE MEDICINE	175
7.1	Quackwatch	182
7.2	Various alternative treatments	184
7.2.1	Immune boosting treatments	184
7.2.2	Direct cancer treatments	185
7.2.3	Unsound devices	186
7.3	Propoganda	187
7.3.1	Derogatory statements on conventional treatment	187
7.3.2	The ploys used by alternative therapy to influence the cancer patient	190
7.4	Medical professionals in alternative medicine	190
7.5	How alternative treatment claims harm cancer patients	192
7.6	Vulnerability to quackery	193
7.7	Alternative and complimentary medicine in breast cancer	194
7.8	Traditional / indigenous medicine	200
7.8.1	Traditional medicine in Sub-Saharan Africa	202
7.8.2	Basic philosophy of traditional medicine	205
7.8.2.1	Reasons for illness in traditional medicine	206
7.8.3	The traditional healer	208
7.8.3.1	Different types of healer	210
7.8.3.2	Thwasa - the calling	211
7.9	Methods of treatment	212
7.10	Traditional healers as part of a team	217
7.11	Cancer treatments and traditional medicine	221
7.11.1	Breast cancer and traditional medicine	222
7.11.2	Traditional medicine and cancer of the cervex	225
7.11.3	Carcinoma of the penis	225
7.11.4	Treatment of some other malignant tumours	226
7.12	Traditional medicine: aids and other sexually related diseases	226
7.13	Traditional medicine and tuberculosis	230
7.14	The traditional healer and psychiatry	230
7.15	Summary	232
8.0	NON COMPLIANCE IN ONCOLOGY SCREENING AND TREATMENT	234
8.1	Cancer screening	234
8.1.1	Breast cancer	236
8.1.1.1	Breast Self Examination (BSE)	237
8.1.1.2	Mammography	238
8.1.1.3	Emotional and Psychological Factors	240
8.1.1.4	Breast Cancer in the Family	241
8.1.1.5	Follow up of Abnormal Results	243
8.1.1.6	Interventions for Breast Cancer Screening	244
8.1.1.6.1	Suggested Interventions	245

8.1.1.6.2	Practical Interventions	246
8.1.1.6.3	Educational and Informative Interventions	247
8.1.1.6.4	Psychological Ways of Improving Compliance:	249
8.1.1.7	Quality of the Physician-Patient Relationship	250
8.1.1.8	Input of Other Health Workers	251
8.1.2	Testicular cancer	252
8.1.3	Prostate cancer	254
8.1.4	Colorectal cancer	255
8.1.5	Pap smear	256
8.1.5.1	Compliance with further screening for an abnormal pap smear	258
8.1.6	Other cancer	260
8.1.7	Personal and circumstantial barriers to compliance in the health professional	262
8.2	Non compliance in oncology treatment	264
8.2.1	The extent of the problem	265
8.2.1.1	Specific cancers	267
8.2.2	Forms of non compliance	269
8.2.2.1	Long term follow up	270
8.2.3	Predictors and reasons for non-compliance	271
8.2.3.1	Side effects	273
8.2.3.2	Psychological reasons for non compliance	274
8.2.3.3	Lag time before diagnosis	276
8.2.4	Childhood and adolescent cancer	279
8.2.5	The psychological aspects of cancer	286
8.2.5.1	Depression and anxiety in cancer	290
8.2.5.1.1	Depression and anxiety related to the symptoms of cancer	292
8.2.5.1.2	Cancer stage and anxiety and depression	296
8.2.5.1.2.1	Diagnosis	296
8.2.5.1.2.2	During stages of treatment	298
8.2.5.1.2.3	Post treatment studies	299
8.2.5.1.3	Depression and anxiety in children's and adolescent cancer	300
8.2.5.1.4	Depression and anxiety in breast cancer	301
8.2.5.1.5	The mastectomy	307
8.2.5.1.6	Depression and anxiety in vicarious experience of cancer	308
8.2.5	Interventions	309
8.2.5.1	Patient-Doctor Communication	309
8.2.5.2	Practical interventions	311
8.2.5.3	Psychiatric interventions	313
8.2.5.4	Psychological and psychotherapeutic interventions	314
8.2.5.4.1	Group psychotherapy	317
8.2.5.4.2	Meditation and music therapy	320
8.2.5.4.3	Empowerment techniques	321
8.2.6	Media impact	322
8.2.7	Summary	325
8.3	Hypothesis and purpose of study	326

VOLUME II

9.0	Methodology	328
9.1	Phase 1	328
9.1.1	Methods and materials	328
9.1.1.1	The subjects used	328
9.1.1.2	Procedure	331
9.1.2	The materials used	333
9.1.2.1	Subject information and consent form	333
9.1.2.2	The general information questionnaire	334
9.1.2.3	MCMI -II (Millon Clinical Multiaxial Inventory - II)	334
9.1.2.3.1	The modifier scales	337
9.1.2.3.2	Personality traits	338
9.1.2.3.3	Severe personality disturbance	342
9.1.2.3.4	Clinical syndromes	343
9.1.2.3.5	Severe clinical syndrome pathology	345
9.1.2.4	The Dysfunctional Attitudes Scale (DAS) (FORM A)	347
9.1.2.5	Beck Hopelessness Scale	349
9.1.2.6	The Social Readjustment Rating Scale (LIFE CHANGE STRESS INDEX)	350
9.1.2.7	Buss-durkee Aggression Scale (HOSTILITY INVENTORY. BDHI)	352
9.1.2.8	The Rotter Internal-external Locus of Control	355
9.1.3	Scoring of data	356
9.1.4	Statistical procedures	357
9.1.4.1	Explanation of stastical terms used in this study	357
9.1.4.2	The Kruskal Wallis median test	358
9.1.4.3	Statistical analysis	359
9.1.4.3.1	MCMI-II (Millon Clinical Multiaxial Inventory II)	359
9.1.4.3.2	The Dysfunctional Attitudes Scale	359
9.1.4.3.3	The Beck Hopelessness Scale	360
9.1.4.3.4	The Buss-Durkee Scale of Aggression	360
9.1.4.3.5	The Rotter Internal-External Locus of Control	360
9.1.5	Construction of a prediction model for the present study	361
9.1.5.1	Introduction	361
9.1.5.2	Construction of the Model	363
9.1.5.3	Theoretical Background	363
9.1.5.4	Model Fitting	365
10.0	Results of Phase 1	366
10.1	The general information questionnaire	366
10.2	The MCMI - II (Millon Clinical Multiaxial Inventory - II)	366
10.3	The dysfunctional attitudes scale	372
10.4	The Beck Hopelessness Scale	373
10.5	The Social Readjustment Raing Scale	373
10.6	The Buss-durkee Scale Of Aggression	374
10.7	The Rotter Internal-external Locus Of Control	375
10.8	Summary of Results	376

10.8.1	Results on the MCMI-11	376
10.8.2	Results on the Remaining Tests	377
11.0	Discussion of results	378
11.1	Discussion of results of the MCMI-11	378
11.1.1	Traits found to be significant at the 5% level	378
11.1.2	Traits found to be significant at the 10% level	397
11.1.3	Traits not found to significantly differentiate between the groups	402
11.1.4	Scales included in the discriminant analysis	411
11.1.4.1	The discriminant model: the interaction and combination of the schizotypal and the debasement scales	411
11.2	The dysfunctional attitudes scale	416
11.3	The Beck hopelessness scale	418
11.4	Life change stress index	420
11.5	The Buss-Durkee scale of aggression	421
11.6	The Rotter internal-external locus of control	424
11.7	Conclusion to phase 1	426
11.8	PTSD and the MCMI	428
12.0	PHASE 2 - A PILOT STUDY	451
12.1	Introduction	451
12.1.1	The revised definitions of PTSD making room for the concept of Medical Trauma and PTSD	455
12.1.2	PTSD and medical conditions	461
12.1.3	PTSD in cancer	465
12.1.3.1	PTSD in breast cancer	468
12.1.3.2	PTSD in bone marrow transplant	472
12.1.3.3	PTSD in paediatric cancer	473
12.1.3.4	Incidence of vicarious trauma in parents of children suffering from cancer	477
12.1.4	The avoidance symptom of PTSD	480
12.1.5	Avoidance in cancer patients	483
12.1.6	PTSD and non compliance	486
12.1.7	Treatment interventions for PTSD in cancer	490
12.1.8	Recognised treatments for PTSD	490
12.1.9	Post traumatic growth	496
12.1.10	Treatment to encourage post traumatic growth	499
12.1.11	Trauma debriefing	503
12.1.12	Trauma debriefing as a preventive intervention for non compliance with medical treatment	507
12.1.12.1	The Wits trauma intervention model	509
12.1.12.2	Traumatic Incident Reduction (TIR)	511
12.2	Hypothesis	514
12.3	The subjects used	514
12.4	Procedure	520
12.5	Materials	520

12.5.1	Instrument used as an intervention: a hybrid adaptation of the wits trauma intervention model	520
12.5.1.1	Telling the story	522
12.5.1.2	Normalizing the symptoms	523
12.5.1.3	Addressing self blame or survivor guilt	523
12.5.1.4	Promoting mastery	523
12.5.1.5	Facilitating the creation of meaning	524
12.6	Results	524
12.6.1	Compliance before and after the medical trauma debriefing intervention	525
12.6.2	Type of cancer and change in behaviour after the intervention	526
12.6.3	Specific aspects of trauma debriefing	529
12.7	Discussion	530
12.8	Limitations of the study	534
12.9	Conclusions	535
12.10	Suggestions for further interventions and research	539
APPENDICES		541
Appendix 1a	Subject Information and Consent Form (Phase 1)	541
Appendix 1b	Subject Information and Consent Form (Phase 2)	542
Appendix 2	THE GENERAL INFORMATION QUESTIONNAIRE	543
Appendix 3	THE MCMI - II (Millon Clinical Multiaxial Inventory - II)	547
Appendix 4	THE DYSFUNCTIONAL ATTITUDES SCALE	553
Appendix 5	THE BECK HOPELESSNESS SCALE	555
Appendix 6	THE SOCIAL READJUSTMENT RAINING SCALE	557
Appendix 7	THE BUSS-DURKEE SCALE OF AGGRESSION	560
Appendix 8	THE ROTTER INTERNAL-EXTERNAL LOCUS OF CONTROL	564
Appendix 9	Format of the Psychotherapeutic Intervention used in Phase 2. A Hybrid Adaptation of the Wits Trauma Intervention Model	569
Appendix 10	Table 15: Types of Cancer and change in Behaviour after the Intervention	574
Appendix 11	Ethics Clearance Certificate	575
REFERENCES		576